BACKGROUND
Vaccinia immune globulin (VIG) administered via the intramuscular route has historically been used for the treatment of complications of smallpox vaccination. Intravenous formulations of VIG are required to improve tolerability and pharmacokinetic profile.
METHODS
We conducted 2 separate studies to evaluate the feasibility of administration of an intravenous formulation of antivacc...
